21st Austria weekly - Marinomed, Wolford, Frequentis (12/04/

21st Austria weekly - Marinomed Wolford Frequentis 12/04/2023 [pic1]Marinomed: Science-based biotech company Marinomed Biotech AG listed on the Vienna Stock Exchange announced further positive results from its clinical study anti-allergic properties of Carragelose nasal spray. The open-label cross-over randomized trial conducted at Challenge Chamber showed that spray can significantly decrease symptoms allergic rhinitis hay fever in patients challenged with their respective allergen. These show exerts a barrier function is not only effective shielding mucosa respiratory viruses but also pollen. This particularly important as suffering are sensitive to viral infections these may worsen underlying disorder.Marinomed Biotech:

Related Keywords

Vienna , Wien , Austria , Ukraine , Australia , Das Familienunternehmen , Industrielle Max Turnauer , Pacific Africa , Vienna Challenge Chamber , Frequentis Group , Vienna Stock Exchange , Marinomed Biotech , Besuchen Sie , Ic1 Marinomed , Science Based , Marinomed , Biotech , Bag , Stock , Exchange , Carragelose , The , Challenge , Chamber , These , This , Disorder Marinomed , Xbiotech ,